****First published March 2018, Now part of MasterVIEW 2020****

# MarketVIEW: Shigella vaccines (CAT: VAMV067)

| | | |
|---|---|---|
| **Product Name** | : | **MarketVIEW:** Shigella vaccines |
| **Description** | : | Vaccine opportunity assessment |
| **Contents** | : | Executive presentation (.pdf) and MS forecast model (.xls) |
| **Therapeutic Area** | : | Novel enteric vaccines |
| **Publication date** | : | March 2018 |
| **Catalogue No** | : | VAMV067 |

## Background

**Shigella** are a highly infectious Gram-negative, non-sporulating, facultative anaerobic bacteria. They produce toxins, which cause a clinical presentation known as Shigellosis. Shigellosis comprises of systemic symptoms such as fever, headache, malaise, anorexia and occasional vomiting. Although shigellosis in otherwise healthy individuals is generally self-limiting, persistent diarrhoea in young children can be serious with the additional risk of seizures, haemolytic uraemic syndrome and other rare complications, which include encephalopathy. Most importantly, Shigella is the fifth most common known cause of diarrhoeal death in children aged <5 years, mostly in the developing world. In 1999, there were estimated to be 164.7 million cases of shigellosis annually globally in 1999, with 1.1 million deaths (WHO Figures).

A Shigella vaccine that can protect against all strains that produce clinically important disease is needed (i.e. a multivalent vaccine). International agencies such as PATH, WHO, and major national agencies such as the NIH are co-funding vaccine development to speed the development of safe, effective and affordable vaccines against Shigella. Some candidates e.g. WRAIR, GSK and PATH are in active clinical development. Approaches followed are cellular, glycol-conjugate, novel antigen and subunit candidates.

The **MarketVIEW** product is a comprehensive MS Excel-based model + summary presentation that forecasts the potential commercial value of Shigella vaccines across endemic and travelers markets to 2035. Each model contains value ($ m) and volume (mio doses) predictions along with launch timeframe, TPP, pricing and penetration estimates. LO/BASE/HI forecast scenarios are included based upon a risk classification of countries in terms of Shigella spp. disease incidence. An up to date review is also given for latest disease background and epidemiology, along with current R&D status.


Warren House, Bells Hill, Bishops Stortford, Herts CM23 2NN, United Kingdom Tel. +44 (0) 1279 654514 e-mail: info@vacZine-analytics.com

# Methodology

**VacZine Analytics** has closely monitored all significant source material pertaining to Shigella spp, pediatric diarrhea, shigellosis and related indications. Source materials used are literature articles, government websites, medical bodies and associations, conference proceedings etc. Previously published research by **VacZine Analytics** in the field of novel bacterial vaccines has also been utilised.

**PRODUCT CONTENTS:**

**Published March 2018 (CAT No: VAMV067)**

****This product is composed of **one** forecast model (.xls)[1] and a summary presentation (.pdf)



[1] Model contents available upon application

**Continued.....**



**SLIDE NUMBER = 70**


Warren House, Bells Hill, Bishops Stortford, Herts CM23 2NN, United Kingdom **Tel.** +44 (0) 1279 654514 **e-mail:** info@vacZine-analytics.com

**PRODUCT COST:**

**VacZine Analytics** will grant a [enter region] license to [enter client name], for the price of:

- FULL PRODUCT - USD **$9995.00**/ GBP **£7140.00#** (Region license)*

# Indicative rate only. Prevailing rate applied to date of transaction.
*A region is North America, Europe or ROW
For orders in the UK, VAT at 20.0% will be added to final invoice total

**HOW TO ORDER:**

To order please contact your region account manager or order direct at orders@vaczine-analytics.com
This report can also be purchased on-line. Please review the **TERMS and CONDITIONS** of purchase.

## BIBLIOGRAPHY


1. Ram PK, et al. Part II. Analysis of data gaps pertaining to Shigella infections in low and medium human development index countries, 1984–2005. Epidemiol Infect 2008;136:577.
2. Thompson CN, et al. The Rising Dominance of Shigella sonnei: An Intercontinental Shift in the Etiology of Bacillary Dysentery. PLoS Negl Trop Dis 2015;9(6):e0003708.
3. BACMAP. Shigella sonnei Ss046. 2016. http://bacmap.wishartlab.com/organisms/262 [Accessed March 2018].
4. Carayol N & Van Nhieu GT. The Inside Story of Shigella Invasion of Intestinal Epithelial Cells. Cold Spring Harb Perspect Med 2013;3:a016717.
5. CDC. Travelers' Health. Shigellosis. 2015. http://wwwnc.cdc.gov/travel/yellowbook/2016/infectious-diseases-related-to-travel/shigellosis [Accessed Jan 2016].
6. NIAID. Shigellosis. 2015. https://www.niaid.nih.gov/topics/shigellosis/Pages/shigellosis.aspx [Accessed March 2018].
7. Böhles N, et al. Vaccines against human diarrheal pathogens. Hum Vaccine Immunotherapeutics 2014;10:1522.
8. Barry EM, et al. Progress and pitfalls in Shigella vaccine research. Nat Rev Gastroenterol Hepatol 2013;10:245.
9. Zaidi MB & Estrada-Garcia T. Shigella: A Highly Virulent and Elusive Pathogen. Curr Trop Med Rep. 2014;1:81.
10. Lanata CF, et al. Global Causes of Diarrheal Disease Mortality in Children ,5 Years of Age: A Systematic Review. PLoS One. 2013;8:e72788.
11. Horizon International Solutions Site. Realizing Water, Sanitation and Hygiene for All. 2014. http://www.solutions-site.org/node/1255 [Accessed March 2018]
12. Livio S, et al. Shigella Isolates From the Global Enteric Multicenter Study Inform Vaccine Development. Clin Infect Dis 2014;59:933.
13. Kotloff KL, et al. Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bull World Health Organ 1999;77:651.
14. Bardhan P, et al. Decrease in Shigellosis-related Deaths without Shigella spp.–specifi c Interventions, Asia. Emerg Infect Dis 2010;16:1718.
15. Scallan E, et al. Foodborne Illness Acquired in the United States—Major Pathogens. Emerg Infect Dis 2011;17:7.
16. Public Health England. Shigella cases 1992 to 2013. 2013. https://www.gov.uk/government/statistics/shigella-cases-1992-to-2013 [Accessed March 2018]
17. WHO. Guidelines for the control of shigellosis, including epidemics due to Shigella dysenteriae type 1. 2005. http://www.who.int/cholera/publications/shigellosis/en/ [Accessed March 2018]
18. George CM, et al. Shigella Infections in Household Contacts of Pediatric Shigellosis Patients in Rural Bangladesh. Emerg Infect Dis 2015;21:2006.
19. Haley CC, et al. Risk factors for sporadic shigellosis, FoodNet 2005. Foodborne Pathog Dis 2010;7:741.
20. Toro C, et al. Shigellosis in Subjects with Traveler's Diarrhea Versus Domestically Acquired Diarrhea: Implications for Antimicrobial Therapy and Human Immunodeficiency Virus Surveillance. Am J Trop Med Hyg 2015;93:491.
21. Warne B, et al. Travel-Related Infection in European Travelers, EuroTravNet 2011. J Travel Med 2014;21:248.
22. Trepanier S, et al. Travel-Related Shigellosis in Quebec, Canada: An Analysis of Risk Factors. J Travel Med 2014;21:304.
23. Baaten GG, et al. Fecal-Orally Transmitted Diseases Among Travelers Are Decreasing Due to Better Hygienic Standards at Travel Destination. J Travel Med 2010;17:322.
24. Rheingans R, et al. Determinants of Household Costs Associated With Childhood Diarrhea in 3 South Asian Settings. Clin Infect Dis. 2012;55:S327.
25. Von Seidlein L, et al. A Multicentre Study of Shigella Diarrhoea in Six Asian Countries: Disease Burden, Clinical Manifestations, and Microbiology. PLoS Med 2006;3:e353
26. Central Intelligence Agency. The World Factbook. 2015. https://www.cia.gov/library/publications/the-world-factbook/rankorder/2119rank.html [Accessed March 2018]
27. Scharff RL. Health-related costs from foodborne illness in the United States. 2010. http://www.pewtrusts.org/en/research-and-analysis/reports/0001/01/01/healthrelated-costs-from-foodborne-illness-in-the-united-states [Accessed March 2018]
28. Niyogi SK. Shigellosis. J Microbiol 2005;43:133.
29. Ashkenazi S, et al. Growing antimicrobial resistance of Shigella isolates. 2003;51:427.
30. Rahman M, et al. Increasing Spectrum in Antimicrobial Resistance of Shigella Isolates in Bangladesh: Resistance to Azithromycin and Ceftriaxone and Decreased Susceptibility to Ciprofloxacin. J Health Popul Nutr 2007;25:158.
31. Sadeghabadi AF, et al. Widespread antibiotic resistance of diarrheagenic Escherichia coli and Shigella species. J Res Med Sci 2014;19(Suppl 1):S51.
32. PATH. Shigellosis and enterotoxigenic Escherichia coli (ETEC). 2015. http://www.path.org/vaccineresources/shigella-etec.php [Accessed March 2018]

33. Levine MM, et al. Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road. Nat Rev Microbiol 2007;5:540.
34. Orr N, et al. Community-Based Safety, Immunogenicity, and Transmissibility Study of the Shigella sonnei WRSS1 Vaccine in Israeli Volunteers. Infect Immun 2005;73:8027
35. Rahman KM, et al. Safety, dose, immunogenicity, and transmissibility of an oral live attenuated Shigella flexneri 2a vaccine candidate (SC602) among healthy adults and school children in Matlab, Bangladesh. Vaccine 2011;29:1347
36. Launay O, et al. Safety and immunogenicity of SC599, an oral live attenuated Shigella dysenteriae type-1 vaccine in healthy volunteers: results of a Phase 2, randomized, double-blind placebo-controlled trial. Vaccine 2009;27:1184
37. Barnoy S, et al. Characterization of WRSs2 and WRSs3, new second-generation virG(icsA)-based Shigella sonnei vaccine candidates with the potential for reduced reactogenicity. Vaccine 2010;28:1642
38. Kotloff KL, et al. Safety and immunogenicity of CVD 1208S, a live, oral DeltaguaBA Deltasen Deltaset Shigella flexneri 2a vaccine grown on animal-free media. Hum Vaccin 2007;3:268
39. Ranallo RT, et al. Immunogenicity and characterization of WRSF2G11: a second generation live attenuated Shigella flexneri 2a vaccine strain. Vaccine 2007;8:2269
40. Passwell JH, et al. Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1-4-year-old Israeli children. Vaccine 2010;28:2231
41. https://clinicaltrials.gov/ct2/show/NCT02646371
42. Gerke C, et al. Production of a Shigella sonnei Vaccine Based on Generalized Modules for Membrane Antigens (GMMA), 1790GAHB, PLoS One 2015;10:e0134478
43. Riddle MS, et al. Safety and immunogenicity of an intranasal Shigella flexneri 2a Invaplex 50 vaccine. Vaccine 2011;29:7009
44. Hatz CF, et al. Safety and immunogenicity of a candidate bioconjugate vaccine against Shigella dysenteriae type 1 administered to healthy adults: A single blind, partially randomized Phase I study. Vaccine 2015;33:4594
45. Kaminski RW, et al. Development and Preclinical Evaluation of a Trivalent, Formalin-Inactivated Shigella Whole-Cell Vaccine. Clin Vaccine Immunol 2014;21:366
46. Heine SJ, et al. Shigella IpaB and IpaD displayed on L. lactis bacterium-like particles induce protective immunity in adult and infant mice. Immunol Cell Biol 2015;93:641
47. Das JK, et al. Vaccines for the prevention of diarrhea due to cholera, shigella, ETEC and rotavirus. BMC Public Health 2013;13(Suppl 3):S11
48. PATH. ETEC and Shigella vaccine development. http://sites.path.org/vaccinedevelopment/diarrhea-rotavirus-shigella-etec/shigella-and-etec-vaccine-development/ [Accessed March 2018]
49. WHO. WHO recommendations for routine immunization - summary tables. 2015. http://www.who.int/immunization/policy/immunization_tables/en/ [Accessed March 2018]
50. Kim SY et al. Health and economic impact of rotavirus vaccination in GAVI-eligible countries. BMC. Pub. Health 2010;10:253
51. WHO. Immunization coverage. 2016. http://apps.who.int/immunization_monitoring/globalsummary/timeseries/tscoveragebcg.html [Accessed March 2018]
52. Lu PJ, et al. Hepatitis A vaccination coverage among adults 18-49 years traveling to a country of high or intermediate endemicity, United States. Vaccine 2013;31:2348.
53. Lopez-Velez R, et al. Spanish Travelers to High-Risk Areas in the Tropics: Airport Survey of Travel Health Knowledge, Attitudes, and Practices in Vaccination and Malaria Prevention. J Travel Med 2007;14:297.
54. Buhler S, et al. A Profile of Travelers—An Analysis From a Large Swiss Travel Clinic. J Travel Med 2014;21:324
55. Heywood AE, et al. A cross-sectional study of pre-travel health-seeking practices among travelers departing Sydney and Bangkok airports. BMC Public Health 2012;12:321.
56. Wilder-Smith A, et al. Travel Health Knowledge, Attitudes and Practices among Australasian Travelers. J Travel Med 2004;11:9.

**TERMS and CONDITIONS:**

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein refered to as "The Company"). (Herein [enter client name] to as "The Client").

**1.** This finished research product is provided is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.

**2.** The Service will commence after written (e-mail) or Fax confirmation stating the Client's acceptance of the Service according the description proposed by the Company.

**3. Cancellation policy**. The Company's cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.

**4. Cancellation rights:** For finished documents - a Clients cancellation rights will last for **seven working days** counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client's cancellation rights have ended.

**5.** Invoicing will **100%** after submission of deliverables to the Client in a form reasonably acceptable to the Client.

**6.** If not purchased on line invoices are payable within **thirty days** of the invoice date.

**7.** All proposals are quoted in **$USD dollars or £GBP** and invoices are to be settled in the same currency.

**8.** The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company's employees and agents with the performance of the Company's obligations to achieve satisfactory completion of the project and approved in writing by the Client.

**9.** Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.

**10.** Please also refer to Master **TERMS and CONDITIONS** available upon request.

**VacZine Analytics**
Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 655926
E-mail: info@vacZine-analytics.com

# About VacZine Analytics:

**VacZine Analytics** is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website www.vacZine-analytics.com